A new enzymatic method for the determination of inulin

Evaluation of a new automated, enzymatic inulin assay using D-fructose dehydrogenase

BACKGROUND

Inulin clearance (Cin) is widely considered to be a gold-standard assessment of glomerular filtration rate (GFR). Although inulin concentrations are commonly determined by the anthrone method, this method has several disadvantages, including a hazardous heating procedure using a strong acid, as well as a nonspecific reaction and being influenced by other saccharides such as glucose.

METHOD

Here, we report the development of a new automated, enzymatic inulin assay. This method uses D: -fructose dehydrogenase (EC1.1.99.11), which does not require NAD or NADP as the electron acceptor, and utilizes oxygen transfer from hydrogen peroxide to an electron acceptor in a sensitive chromophoric system. This method allows rapid and accurate determination of inulin concentrations, and takes only 15 min on automated analyzers. We evaluated this new assay and compared it with the anthrone method.

RESULTS

The detection limit value and linearity of the new method were 5 mg/l and up to 300 mg/l, respectively. The within-run precision coefficient of variations (CVs) for serum and for urine were 2.05 +/- 0.79% (mean +/- SEM; n = 3) and 0.92 +/- 0.24%, respectively, and the between-run precision CVs for serum and for urine were 1.91 +/- 0.72% and 1.86 +/- 0.17%, respectively. No influence of glucose was observed with the new method, while a positive influence of 38.7% was observed with the anthrone method. However, neither method was influenced by fructose (3.0 mg/l in serum or 30 mg/l in urine). The analytical recovery rates of inulin were 97.8 +/- 0.7% (mean +/- SEM; n = 6) in serum and 99.0 +/- 0.4% in urine using the enzymatic method. We compared results for the enzymatic method and the anthrone method using 46 serum samples and 46 urine samples. Bland-Altman plots showed no significant difference between the two methods for the serum samples. However, inulin recovery in the urine samples measured by the enzymatic method was about 5% higher than that obtained by the anthrone method.

CONCLUSION

The new enzymatic assay offers a more convenient and more accurate measurement of inulin and may be suitable for routine procedures by automated analyzers in clinical laboratories.

Para-capillary electron-dense deposits reduce glomerular filtration in patients with primary glomerular diseases

BACKGROUND

Electron-dense deposits are often found around glomerular capillary lumens in patients with glomerulonephritis, forming a portion of the blood-urine barrier (BUB).

METHODS

Four hundred and four patients with primary glomerular diseases or donors for living-related kidney transplantation who underwent both percutaneous renal biopsy and renal clearance tests were included in the study. Sodium thiosulfate and paraamino hippurate double-clearance studies were performed with catheterized urinary collection. The filtration fraction (FF) was determined as follows: FF = sodium thiosulfate clearance/paraamino hippurate clearance (CPAH: ). Histomorphometric analyses were performed in 53 patients with overt para-capillary electron-dense deposits (PCEDD) by electron microscopic observations.

RESULTS

Patients with membranous nephropathy and membranoproliferative glomerulonephritis showed significantly lower levels of FF than the donors for living-rebated kidney transplantation (normal controls). FF levels were significantly lower in patients with PCEDD than in those without (P < 0.001), while the levels of mean blood pressure and CPAH: were comparable in the two groups. The PCEDD/BUB ratio demonstrated a significant negative correlation with FF (P < 0.0001; r(2) = 0.331). Patients with a ratio of 0.5 or more showed significantly lower FF levels than those with a ratio of 0.25 or less.

CONCLUSIONS

PCEDD significantly affected FF levels in patients with primary glomerular diseases. FF may not be an accurate indicator of intraglomerular blood pressure in patients with overt PCEDD.

Progesterone increases plasma volume independent of estradiol

Adequate plasma volume (PV) and extracellular fluid (ECF) volume are essential for blood pressure and fluid regulation. We tested the hypotheses that combined progesterone (P4)-estrogen (E2) administration would increase ECF volume with proportional increases in PV, but that P4would have little independent effect on either PV or ECF volume. We further hypothesized that this P4-E2-induced fluid expansion would be a function of renin-angiotensin-aldosterone system stimulation. We suppressed P4and E2with a gonadotropin-releasing hormone (GnRH) antagonist in eight women (25 ± 2 yr) for 16 days; P4(200 mg/day) was added for days 5–16 (P4) and 17β-estradiol (2 × 0.1 mg/day patches) for days 13–16 (P4-E2). On days 2 (GnRH antagonist), 9 (P4), and 16 (P4-E2), we estimated ECF and PV. To determine the rate of protein and thus water movement across the ECF, we also measured transcapillary escape rate of albumin. In P4, [Formula: see text] increased from 2.5 ± 1.3 to 12.0 ± 2.8 ng/ml ( P < 0.05) with no change in [Formula: see text] (21.5 ± 9.4 to 8.6 ± 2.0 pg/ml). In P4-E2, plasma concentration of P4remained elevated (11.3 ± 2.7 ng/ml) and plasma concentration of E2increased to 254.1 ± 52.7 pg/ml ( P < 0.05). PV increased during P4(46.6 ± 2.5 ml/kg) and P4-E2(48.4 ± 3.9 ml/kg) compared with GnRH antagonist (43.3 ± 3.2 ml/kg; P < 0.05), as did ECF (206 ± 19, 244 ± 25, and 239 ± 27 ml/kg for GnRH antagonist, P4, and P4-E2, respectively; P < 0.05). Transcapillary escape rate of albumin was lowest during P4-E2(5.8 ± 1.3, 3.5 ± 1.7, and 2.2 ± 0.4%/h for GnRH antagonist, P4, and P4-E2, respectively; P < 0.05). Serum aldosterone increased during P4and P4-E2compared with GnRH antagonist (79 ± 17, 127 ± 13, and 171 ± 25 pg/ml for GnRH antagonist, P4, and P4-E2, respectively; P < 0.05), but plasma renin activity and plasma concentration of ANG II were only increased by P4-E2. This study is the first to isolate P4effects on ECF; however, the mechanisms for the ECF and PV expansion have not been clearly defined.

Effects of estrogen and progesterone administration on extracellular fluid

To determine the effect of estrogen and progesterone on plasma volume (PV) and extracellur fluid volume (ECFV), we suppressed endogenous estrogen and progesterone by using the gonadotropin-releasing hormone (GnRH) antagonist ganirelix acetate in seven healthy women (22 ± 1 yr). Subjects were administered GnRH antagonist for 16 days. Beginning on day 5 of GnRH antagonist administration, subjects were administered estrogen (E2) for 11 days, and beginning on day 12 of GnRH antagonist administration, subjects added progesterone (E2-P4) for 4 days. On days 2, 9, and 16 of GnRH antagonist administration, we estimated ECFV (inulin washout), transcapillary escape rate of albumin (TERalb), and PV (Evans blue dye). Plasma E2concentration increased from 17.9 ± 4.5 (GnRH antagonist) to 195.9 ± 60.1 (E2, P < 0.05) to 245.6 ± 62.9 pg/ml (E2-P4, P < 0.05). Compared with GnRH antagonist (1.3 ± 0.5 ng/ml), plasma P4concentration was unchanged during E2(0.9 ± 0.3 ng/ml) and increased to 9.4 ± 3.1 ng/ml during E2-P4( P < 0.05). Both E2(44.1 ± 3.1 ml/kg) and E2-P4(47.7 ± 2.8 ml/kg) increased PV compared with GnRH antagonist (42.8 ± 1.3 ml/kg, P < 0.05). Within-subjects TERalbwas a strong negative predictor of PV (mean r = 0.92 ± 0.03, P < 0.05), and TERalbwas lowest during E2-P4(5.7 ± 0.5, 4.1.0 ± 1.1, and 2.8 ± 0.9%/h, P < 0.05, for GnRH antagonist, E2, and E2-P4, respectively). ECFV was reduced during E2(227 ± 31 ml/kg, P < 0.05) compared with both GnRH antagonist (291 ± 37 ml/kg) and E2-P4(283 ± 19 ml/kg). Thus the percentage of extracellular fluid in the plasma compartment increased to 21.0% ( P < 0.05) during E2compared with GnRH antagonist (16.1%) and E2-P4(17.2%) admistration. Thus E2increased PV via actions on the capillary endothelium to lower TERalband favor intravascular water retention, whereas during E2-P4PV increased via the combined responses of ECFV expansion and lower TERalb.

Animal versus plant protein meals in individuals with type 2 diabetes and microalbuminuria: effects on renal, glycemic, and lipid parameters

OBJECTIVE

To determine, for individuals with type 2 diabetes and microalbuminuria, the effects of 6 weeks of meals containing plant-based protein (PP) versus meals with predominantly animal-based protein (AP) on renal function and secondarily on glycemia, lipid levels, and blood pressure.

RESEARCH DESIGN AND METHODS

In a randomized crossover trial, we compared 6 weeks of meals containing only PP with meals containing primarily AP (60% animal, 40% plant) in 17 subjects with type 2 diabetes and microalbuminuria treated with diet and/or oral antidiabetic agents. Protein content was equivalent to the average American diet, and calories provided weight maintenance. Nutrients were equivalent between the two diets. Meals were prepared and packaged by a metabolic kitchen staff and were sent home weekly. At the beginning and end of each 6-week period, subjects were studied for 36 h on a metabolic unit.

RESULTS

There were no significant differences between diets for glomerular filtration rate, renal plasma flow, albumin excretion rate, total cholesterol, HDL cholesterol, triglyceride area under the curve (AUC), glucose and insulin AUC, HbA(1c,) blood pressure, or serum amino acids. For both diets, at the end of the treatment periods as compared with baseline, total cholesterol was significantly lower (PP and AP: from 4.75 to 4.34 mmol/l, P < 0.01), HbA(1c) had significantly improved (PP: from 8.1 to 7.5%, P < 0.01; AP: from 7.9 to 7.4%, P < 0.01), and diastolic blood pressure was significantly lower (PP: from 83 to 80 mmHg, P < 0.02; AP: from 82 to 78, P < 0.02).

CONCLUSIONS

There is no clear advantage for the recommendation of diets containing only PP rather than diets containing protein that is primarily animal-based for individuals with type 2 diabetes and microalbuminuria. There are, however, potential lipid, glycemic, and blood pressure benefits for following a carefully constructed, weight-maintaining, healthy diet, regardless of protein source.

Rapid microtiter plate assay for determination of inulin in human plasma and dialysate

A rapid, sensitive, and reproducible microtiter plate assay for the determination of inulin in human plasma, dialysate, and phosphate-buffered saline (PBS) was developed. Plasma or PBS samples (100 microl aliquots) were prepared by the addition of indole-3-acetic acid (150 microl) and HCl (3 ml) and then briefly vortex-mixed. Samples were then incubated in a 60 degrees C water bath for 20 min, cooled in a room temperature water bath for 40 min, then diluted with deionized, distilled water (DDW; 3 ml) and again vortex-mixed. Finally, an aliquot (200 microl) of each sample was transferred to a 96-well microtiter plate and read spectrophotometrically at 490 nm. Dialysate samples were processed in a similar manner, but required an initial enzymatic step in order to remove dextrose and minimize assay interference. Samples (100 microl aliquots) were prepared by the addition of glucose oxidase/catalase solution (100 microl), briefly vortex mixed, and then incubated in a 37 degrees C water bath for 60 min, samples were then reacted with indole-3-acetic acid as before. Calibration curves were linear over the concentration range of 0.5-4 mg/ml or 0.025-0.4 mg/ml for plasma or PBS and dialysate, respectively; correlation coefficients (r(2)) were >0.99. The intra- and inter-day coefficients of variation in plasma, PBS, and dialysate were <15%. This method is well suited for the rapid analysis of large numbers of samples and is currently being used for in vitro investigations of solute removal by hemodialysis.

Pharmacokinetic aspects of measurement of glomerular filtration rate in the dog: a review

Glomerular filtration rate (GFR) is estimated by means of clearance, defined as the volume of plasma that has been cleared of a particular substance per unit time. Glomerular filtration rate may be estimated by measuring the renal clearance of a filtration marker using data from both urine and plasma or by plasma clearance using only plasma data. Several alternative pharmacokinetic models are used for the calculation of clearance using various filtration markers with slightly different pharmacokinetic properties. The purpose of this article is to discuss how the choice of marker and pharmacokinetic model may influence estimated GFR values and to elucidate commonly used methods and reported GFR values in the dog.

Renal haemodynamic characteristics in patients with lupus nephritis

OBJECTIVE

To clarify the characteristics of renal haemodynamics in patients with lupus nephritis (LN).

METHODS

The glomerular filtration rate (GFR) and renal plasma flow (RPF) of 37 patients with active LN were studied longitudinally over an interval of 8 to 144 weeks during treatment with corticosteroids or cytotoxic drugs, or both. All patients had clinical renal disorders and underwent renal biopsies.

RESULTS

Analysis of renal biopsy specimens showed that 31 patients had class IV LN. Class II, III, and VLN were present in two patients each. The average GFR increased significantly from 65.4 (SD 33.0) in the pretreatment stage to 86.6 (31.6) ml/min in the post-treatment stage, accompanied by an improvement in urinary or immunological abnormalities, or both. On the other hand, RPF decreased significantly from 625.2 (243.0) to 519.8 (179.0) ml/min. Therefore, the filtration fraction (FF) increased significantly from 10.7 (4.3)% to 16.8 (3.7)%. Low FF was recognised predominantly in patients with class IV LN, but was also observed in patients with other classes. The FF returned towards normal irrespective of the degree of GFR recovery. No significant changes were observed in the levels of blood pressure.

CONCLUSION

A reduction in GFR out of proportion to the reduction in RPF as demonstrated by the low FF values was related to the severity of LN or disease activity, or both. Therefore, relative evaluation of GFR and RPF, namely the determination of FF, may be a useful clinical parameter to determine the status of LN.